flow trial semaglutide kidney outcomes Chronic Disease FLOW trial Ozempic® (semaglutide injection)

The oxidative stress theory of disease: levels of evidence and epistemological aspects

doi: 10.1016/j.intimp.2007.12.006

Krall AS, Xu S, Graeber TG, Braas D, Christofk HR

Kwon for help with the CLAMS assay

Clinical trial data have generated significant interest in retatrutide because of its substantial weight-loss results, including Phase 3 findings showing average body weight reductions of more than 30% at the highest studied dose over 80 weeks

As a member of the glucagon-like peptide-1 (GLP-1) receptor agonists class, semaglutide offers a novel approach to treatment, targeting not only the symptoms but also some of the underlying mechanisms of these diseases